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Abstract—The angiotensin-converting enzyme (ACE) I/D and the -adducin (ADD1) Gly460Trp polymorphisms are
associated with cardiovascular risk factors. In a prospective population study and in cell models, we investigated the
combined effects of these 2 polymorphisms. We randomly recruited 1287 white subjects (women: 50.0%; mean age:
55.9 years). We obtained outcomes from registries and repeat examinations (median 3). Over 9.0 years (median), 178
fatal or nonfatal cardiovascular events occurred. In ADD1 Trp allele carriers, the multivariate-adjusted hazard ratios
associated with ACE DD versus I were 1.72 (P0.007) for total mortality, 2.35 (P0.02) for cardiovascular mortality,
2.02 (P0.005) for all cardiovascular events, and 2.59 (P0.03) for heart failure. In contrast, these hazard ratios did
not reach significance in ADD1 GlyGly homozygotes (0.08P0.90). The positive predictive value and attributable risk
associated with ACE DD homozygosity combined with mutated ADD1 were 36.2% and 10.3%, respectively. To clarify
our epidemiological observations, we investigated the effects of mutated human ADD1 on the membrane-bound ACE
activity in fibroblasts from 51 volunteers and in transfected human embryonic kidney cells (31 experiments). In fibroblasts
(5.10 versus 3.63 nanomoles of generated hippuric acid per milligram of protein per minute; P0.0021) and human
embryonic kidney cells (1.086 versus 0.081 nmol/mg per minute; P0.017), the membrane-bound ACE activity increased in
the presence but not absence of the ADD1 Trp allele. In conclusion, the combination of ACE DD homozygosity and mutated
ADD1 worsened cardiovascular prognosis to a similar extent as classic risk factors, possibly because of increased
membrane-bound ACE activity in subjects carrying the ADD1 Trp allele. (Hypertension. 2007;49:1291-1297.)
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In monogenic diseases with typical Mendelian inheritance,such as phenylketonuria1 or thalassanemia,2 penetrance is
under the influence of endogenous modulators, lifestyle, and
environmental factors. The same mutation can, therefore,
produce a wide spectrum of clinical manifestations, ranging
from early onset debilitating disease to just mild symptoms at
advanced age. This principle is even more applicable to
polygenic cardiovascular disorders, in which many genes to a
small and variable extent contribute to a common disease.
The insertion–deletion polymorphism of the angiotensin-
converting enzyme (ACE) gene (ACE I/D) is among the most
frequently examined genetic variants in cardiovascular med-
icine.3 It affects the plasma level of ACE3 and the generation
of angiotensin II in the kidney,4–6 arterial wall,7 and heart.8
The sodium content of the body modulates the effects of
angiotensin II.9 Substitution of glycine by tryptophan in the
cytoskeleton protein -adducin (ADD1 Gly460Trp) enhances
tubular sodium reabsorption in the kidney.9,10 Studies of
never-treated hypertensive patients11,12 and European13–15 and
Chinese populations16 suggested that cardiovascular risk
factors are associated with the ACE D allele, but only in the
presence of mutated ADD1. Here, we report the results of a
prospective population study and cell experiments, which
further clarify the interaction between these 2 polymorphisms
from a prognostic and mechanistic point of view.
Methods
Prospective Population Study
The University of Leuven Ethics Committee approved the Flemish
Study on Environment, Genes and Health Outcomes.13,17 From
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August 1985 until December 2005, we randomly recruited a family
based population sample from a geographically defined area in
Northern Belgium. The study population included 3108 subjects.
The participation rate among the subjects contacted averaged 64.3%.
Blood for DNA extraction could not be obtained from 422 partici-
pants, because they did not consent (n150), had died (n110),
were terminally ill (n30), or had moved out of the area (n132).
We also excluded 323 teenagers and 1076 adults with lower than
median age at enrollment (41.4 years), because during follow-up
only 12 (0.9%) of these 1399 subjects had experienced a fatal or
nonfatal cardiovascular event. Thus, the number of participants
statistically analyzed totaled 1287.
At the enrollment home visit, trained nurses measured anthropo-
metric characteristics and blood pressure. They also administered a
questionnaire to collect information about each subject’s medical
history, smoking and drinking habits, and intake of medications.
Blood pressure was the average of 5 consecutive readings. Hyper-
tension was defined as a blood pressure of 140 mm Hg systolic or
90 mm Hg diastolic or as the use of antihypertensive drugs. Body
mass index was weight in kilograms divided by the square of height
in meters. Venous blood samples were drawn for DNA extraction
and the measurement of serum cholesterol. Hypercholesterolemia
was a serum level of 5.16 mmol/L (200 mg/dL)18 or treatment
with lipid-lowering drugs. Genomic DNA from white blood cells
was amplified and genotyped for ACE and ADD1, as described
previously.13
Via the National Population Registry (Rijksregister) in Brussels,
Belgium, we ascertained vital status of all of the participants until
December 31, 2005. We obtained the International Classification of
Disease codes for the immediate and underlying causes of death from
the Flemish Registry of Death Certificates. In 1089 subjects, we also
collected information on the incidence of nonfatal events via
follow-up visits with repeat administration of the same standardized
questionnaire as that used at baseline. Follow-up was available at 1,
2, 3, or more occasions in 346, 286, 315, and 340 subjects,
respectively. Physicians blinded with regard to the genetic results
ascertained the diseases reported on the death certificates or via the
questionnaires against the records held by general practitioners or
hospitals. Coronary events included fatal and nonfatal myocardial
infarction and procedures for coronary revascularization. Cardiac
events consisted of fatal and nonfatal heart failure and coronary
events. Fatal and nonfatal cardiovascular events were composed of
cardiac end points, stroke not including transient ischemic attacks,
aortic aneurysm, cor pulmonale, and pulmonary embolism. For all of
the end points, we censored subjects from further analysis after the
occurrence of a first event.
We used the SAS 9.1 software (SAS Institute) for database
management and statistical analysis. We compared means and
proportions by the standard normal z test and the 2 statistic,
respectively, and survival curves by Kaplan–Meier survival function
estimates and the log-rank test. We used Cox proportional hazard
regression as implemented in the PROC SURVIVAL procedure of
the SUDAAN 9.0 software (Research Triangle Institute) to calculate
hazard ratios, while allowing for covariates, confounders, and family
clusters. The baseline characteristics considered as covariates in Cox
regression were sex, age, systolic blood pressure, body mass index,
smoking, intake of alcohol, use of antihypertensive drugs, serum
cholesterol, and previous cardiovascular complications. For all of the
cardiovascular events, we computed the positive predictive value of
a risk factor as [RD]/[(G/100)(R1)1], where R is the multi-
variate-adjusted hazard ratio, D is the incidence of cardiovascular
disease (19.7%), and G is the prevalence of the risk factor expressed
in percent.19 The attributable risk is given by
[(G/100)(R1)100]/[(G/100)(R1)1].19
Measurement of ACE Activity in
Experimental Studies
The ethics committee of the University Vita Salute, Milan, approved
the study. We genotyped fibroblast harvested from forearm skin
biopsies for ACE and ADD1. Fifty-one volunteers gave informed
written consent. The fibroblasts were grown to confluence in
minimum Eagle’s medium with 10% FBS and 100 IU/mL of
penicillin/streptomycin. At least 72 hours before the ACE assay, the
fibroblasts were made quiescent in minimum Eagle’s medium with
0.3% FBS. We measured ACE activity in cell homogenates20 and the
membrane-bound activity21 by hydrolysis of the synthetic substrate
hippuryl-L-histidyl-L-leucine (Sigma-Aldrich),22 followed by a high-
performance liquid chromatography quantification of the hippuric
acid formed during incubation.23 We expressed ACE activity in
nanomoles of hippuric acid produced per milligram of protein per
minute. We used Student’s t test for unpaired observations with
2-tailed P levels to compare ACE activity across genotypes.
Human embryonic kidney (HEK) cells, purchased from the
European Collection of Animal Cell Cultures (85120602), were
cultured in monolayer in DMEM (Gibco BRL) with 5% bovine
serum (Cambrex), 1% non-essential amino acids (Sigma-Aldrich),
and 100 IU/mL of penicillin/streptomycin (Gibco BRL). We ob-
tained human wild-type (Gly460 and Ser586) and mutated (Trp460
and Cys586) ADD1 by site-directed mutagenesis of an expression
vector for hemagglutinin-tagged human adducin (aa1–737,
pCMVneoHA-ADD1) using the QuickChange mutagenesis kit
(Stratagene). For transfection, we used the Cal Phos mammalian
transfection kit (Clontech). We selected stable transfectants by
addition of 0.9 mg/mL of G418 sulfate (Stratagene). We quantified
the overexpression of protein in Western blots using a monoclonal
antibody against ADD1 and a polyclonal antibody against the
hemagglutinin tag (Upstate) and the Odyssey Infrared Imaging
System (Li-Cor Biosciences). For each of the 2 ADD1 variants, we
generated 3 lines of transfected HEK cells. In each cell line, we
measured membrane-bound ACE activity21 in 4 to 6 separate
experiments. After being grown to confluence, the HEK cells were
scraped, gently centrifuged, and resuspended in assay buffer con-
taining 1 mmol/L of hippuryl-L-histidyl-L-leucine.
Results
Prospective Population Study
The 1287 participants included 643 women (50.0%); 522
hypertensive patients (40.6%) of whom 257 (49.2%) were on
antihypertensive drug treatment; and 976 hypercholesterol-
emic patients (75.8%) of whom 44 (4.5%) were on treatment
with lipid-lowering drugs. Women compared with men
(P0.05) had lower systolic (130.3 versus 132.5 mm Hg) and
diastolic (77.8 versus 79.8 mm Hg) blood pressures and less
frequently reported smoking (22.6% versus 35.4%), intake of
alcohol (12.1% versus 38.4%), and previous cardiovascular
complications (4.0% versus 7.9%). The frequencies of the
ACE genotypes (DD 24.6%, ID 51.6%, and II 23.8%;
P0.25) and the ADD1 genotypes (GlyGly 58.6%, GlyTrp
36.1%, and TrpTrp 5.3%; P0.74) did not deviate from
Hardy–Weinberg proportions. The baseline characteristics of
the study participants by ACE and ADD1 genotypes appear in
Table 1.
Median follow-up was 9.0 years (5th to 95th percentile
interval: 0.9 to 20.2 years) for fatal end points and 7.2 years
(5th to 95th percentile interval: 1.3 to 16.7 years) for all of the
fatal and nonfatal cardiovascular events combined. Partici-
pants with follow-up information available at 1 or 2 occasions
(n632) as compared with those with more frequent
follow-up (n655) had similar baseline characteristics with
the exception of small differences in age (57.7 versus 54.2
years, respectively; P0.001), systolic blood pressure (132.6
versus 130.2 mm Hg; P0.02), and serum cholesterol (5.84
versus 6.06 mmol/L; P0.001). Of 220 deaths, 90 (40.9%)
were because of cardiovascular causes. The incidence of fatal
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and nonfatal cardiovascular outcomes totaled 178, including
91 coronary events, 46 cases of heart failure, and 41 strokes.
In single-gene analyses (Table 2) with adjustments applied
for family clusters and baseline characteristics including sex,
age, body mass index, systolic blood pressure, smoking,
alcohol intake, serum cholesterol, use of antihypertensive
drugs, and previous cardiovascular disease, ACE DD ho-
mozygosity compared with the I allele predicted total mor-
tality (hazard ratio: 1.43; P0.014) and heart failure (hazard
ratio: 2.33; P0.006). Although not formally significant,
trends were similar for cardiovascular mortality (hazard ratio:
1.61; P0.062) and all of the cardiovascular events (hazard
ratio: 1.34; P0.09). In similarly adjusted single-gene anal-
yses, the ADD1 Trp allele compared with GlyGly homozy-
gosity predicted heart failure (hazard ratio: 2.21; P0.006)
but none of the other outcomes (Table 2).
The Figure shows Kaplan–Meier survival function esti-
mates for all of the cardiovascular events. In subjects with
mutated ADD1 (P0.03), but not in GlyGly homozygotes
(P0.70), ACE DD homozygosity conferred a higher overall
cardiovascular risk than the I allele. Table 3 shows that with
similar adjustments applied as in the single-gene analyses,
none of the hazard ratios associated with ACE DD homozy-
gosity reached significance (0.08P0.90) in ADD1 GlyGly
homozygotes. In contrast, in ADD1 Trp allele carriers, the
corresponding hazard ratios were significant for total mortal-
ity (hazard ratio: 1.72; P0.007), cardiovascular mortality
(hazard ratio: 2.35; P0.02), all cardiovascular events (haz-
ard ratio: 2.02; P0.005), and heart failure (hazard ratio:
2.59; P0.03), with a similar trend for cardiac events (hazard
ratio: 1.79; P0.057). The interaction between the ACE and
ADD1 genes reached statistical significance for all of the fatal
TABLE 1. Clinical Features by ACE and ADD1 Genotypes
Characteristic
ACE Genotypes ADD1 Genotypes
II  ID
(n971)
DD
(n316) P
GlyGly
(n754)
GlyTrp  TrpTrp
(n533) P
MeanSD of entry characteristic
Age, y 55.710.6 56.410.6 0.36 55.310.5 56.710.7 0.03
Body mass index, kg/m2 26.84.3 26.94.4 0.74 26.94.6 26.84.0 0.50
Systolic blood pressure, mm Hg 131.017.9 132.418.5 0.26 131.317.9 131.518.3 0.82
Diastolic blood pressure, mm Hg 78.89.7 79.09.1 0.69 79.09.4 78.69.8 0.43
Serum cholesterol, mmol/L 5.961.21 5.921.16 0.62 5.921.19 5.991.21 0.30
No. (%) with entry characteristic
Women 494 (50.9) 149 (47.2) 0.27 369 (48.9) 274 (51.4) 0.40
Current smokers 296 (30.5) 77 (24.4) 0.04 221 (29.3) 152 (28.5) 0.80
Consuming alcohol 245 (25.2) 80 (25.3) 0.99 195 (25.9) 130 (24.4) 0.56
Hypertensive patients 388 (40.0) 134 (42.4) 0.47 294 (39.0) 228 (42.8) 0.19
On antihypertensive medication 193 (19.9) 64 (20.3) 0.87 144 (19.1) 113 (21.2) 0.36
Cardiovascular history* 60 (6.2) 17 (5.4) 0.68 44 (5.8) 33 (6.2) 0.81
P values are for the differences between genotypes.
*Previous cardiovascular complications consisted of myocardial infarction, coronary revascularization, heart failure, stroke, aortic
aneurysm, cor pulmonale, and pulmonary embolism.
TABLE 2. Hazard Ratios for Cardiovascular Outcomes in Single-Gene Analyses
Event Type
ACE DD vs I ADD1 Trp vs GlyGly
Cases DD/I* Hazard Ratio (95% CI)† P Cases Trp/GlyGly* Hazard Ratio (95% CI)† P
Mortality
Total 62/158 1.43 (1.08 to 1.90) 0.014 96/124 1.16 (0.88 to 1.54) 0.30
Cardiovascular 28/62 1.61 (0.98 to 2.64) 0.062 41/49 1.25 (0.79 to 1.97) 0.34
Fatal and nonfatal events‡
Cardiovascular 48/130 1.34 (0.95 to 1.90) 0.09 80/89 1.19 (0.88 to 1.60) 0.26
Cardiac 34/86 1.36 (0.88 to 2.11) 0.17 57/63 1.26 (0.86 to 1.85) 0.24
Coronary 22/69 1.04 (0.63 to 1.72) 0.88 38/53 0.93 (0.59 to 1.48) 0.77
Heart failure 19/27 2.33 (1.28 to 4.25) 0.006 28/18 2.21 (1.25 to 3.91) 0.006
Stroke 12/29 1.29 (0.66 to 2.52) 0.45 14/27 0.74 (0.38 to 1.44) 0.38
*Number of ACE DD/I subjects at risk amounted to 316/971 for mortality and 268/821 for fatal and nonfatal events. For ADD1
Trp/GlyGly, these numbers were 533/754 and 464/625, respectively.
†Hazard ratios for ACE DD vs I were adjusted for family clusters and baseline characteristics: sex, age, body mass index, systolic
blood pressure, serum cholesterol, smoking, alcohol intake, use of antihypertensive drugs, and previous cardiovascular diseases.
‡A total of 198 participants were alive on December 31, 2005, but were not followed up for nonfatal events.
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and nonfatal cardiovascular events (P0.02) but not for the
other end points under study (P0.20). Sensitivity analyses
showed consistent results after exclusion of the participants
who, at enrollment, had a history of cardiovascular compli-
cations (Table S1 available online at http://hyper.ahajournal-
s.org) or who were on antihypertensive drug treatment at
baseline (see Table S2).
In all of the participants, the positive predictive value and
attributable risk associated with the combination of ACE DD
homozygosity and mutated ADD1 were 36.2% and 10.3%,
respectively. Considering classic risk factors at enrollment,
these estimates were 24.5% and 10.4% for smoking, 21.1%
and 25.0% for hypercholesterolemia, and 25.7% and 21.8%
for hypertension, respectively.
Experimental Studies
In human fibroblasts, the membrane-bound ACE activity was
similar irrespective of the presence (n37; 3.97 nmol/mg per
minute; SE: 0.28 nmol/mg per minute) or absence of the ACE D
allele (n14; 4.39 nmol/mg per minute; SE: 0.45 nmol/mg per
minute; P0.43). In contrast, the membrane-bound ACE activ-
ity was higher in fibroblasts carrying the ADD1 460Trp allele
(n21; 5.10 nmol/mg per minute; SE: 0.35 nmol/mg per
minute) compared with those not carrying the mutated ADD1
allele (n30; 3.63 nmol/mg per minute; SE: 0.29 nmol/mg per
minute; P0.0021). In homogenates of human fibroblasts, the
ACE activity tended to be higher in ACE D allele carriers
(n32; 3.48 nmol/mg per minute; SE: 0.24 nmol/mg per
minute) than in noncarriers (n13; 2.76 nmol/mg per minute;
Kaplan–Meier survival function estimates for all of the cardiovascular events in ACE DD homozygotes compared with ACE I allele carri-
ers in ADD1 GlyGly homozygotes (left) and in ADD1 Trp allele carriers (right). P values were derived from the log-rank test.
TABLE 3. Hazard Ratios for Cardiovascular Outcomes in ACE DD vs I Carriers by ADD1 Genotype
Event Type
ADD1 GlyGly Homozygotes ADD1 Trp Allele Carriers
Cases DD/I* Hazard Ratio (95% CI)† P Cases DD/I* Hazard Ratio (95% CI)† P
Mortality
Total 31/93 1.24 (0.82 to 1.88) 0.31 31/65 1.72 (1.16 to 2.54) 0.007
Cardiovascular 14/35 1.51 (0.75 to 3.04) 0.24 14/27 2.35 (1.14 to 4.77) 0.02
Fatal and nonfatal events‡
Cardiovascular 22/76 0.97 (0.58 to 1.62) 0.90 26/54 2.02 (1.24 to 3.29) 0.005
Cardiac 15/48 1.20 (0.65 to 2.24) 0.56 19/38 1.79 (0.98 to 3.26) 0.057
Coronary 11/42 1.07 (0.52 to 2.21) 0.85 11/27 1.14 (0.56 to 2.29) 0.72
Heart failure 7/11 2.42 (0.89 to 6.56) 0.08 12/16 2.59 (1.08 to 6.21) 0.03
Stroke 8/19 1.38 (0.60 to 3.17) 0.44 4/10 1.28 (0.43 to 3.83) 0.66
*Among ADD1 GlyGly homozygotes, the number of ACE DD/I subjects at risk amounted to 180/574 for mortality and 149/476 for
fatal and nonfatal events. Among ADD1 Trp allele carriers, these numbers were 136/397 and 119/345, respectively.
†Hazard ratios for ACE DD vs I were adjusted for family clusters and baseline characteristics: sex, age, body mass index, systolic
blood pressure, serum cholesterol, smoking, alcohol intake, use of antihypertensive drugs, and previous cardiovascular diseases.
‡A total of 198 participants were alive on December 31, 2005, but were not followed up for nonfatal events.
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SE: 0.26 nmol/mg per minute; P0.089) and in ADD1 Trp
carriers (n19; 3.69 nmol/mg per minute; SE: 0.36 nmol/mg per
minute) compared with the corresponding noncarriers (n23;
3.03 nmol/mg per minute; SE: 0.20 nmol/mg per minute;
P0.091). HEK cells transfected with mutated human ADD1
had higher membrane-bound ACE activity (n16; 1.086
nmol/mg per minute; SE: 0.064 nmol/mg per minute) than those
transfected with the wild-type ADD1 (n15; 0.081 nmol/mg per
minute; SE: 0.055 nmol/mg per minute; P0.017).
Discussion
The key finding of our study was that in a randomly recruited
sample of middle-aged and older white subjects, ACE DD
homozygosity predicted total and cardiovascular mortality
and the incidence of cardiovascular events in carriers of the
mutated ADD1 but not in subjects carrying the wild-type
ADD1. These findings translate previously observed11–15
associations of cardiovascular risk factors with these 2
polymorphisms into hard cardiovascular outcomes. Further-
more, in ex vivo studies, human fibroblasts showed higher
membrane-bound ACE activity in the presence of the ADD1
Trp allele. We corroborated the latter observation in cell
membranes of HEK cells transfected with the human mutated
and wild-type ADD1. Based on this replication, we believe
that our ex vivo finding might be extrapolated to human
kidney cells.
In line with expert opinion,24 we opted for the candidate
gene approach, which relies on solid knowledge of patho-
physiologic pathways and accounts for the context depen-
dency of genetic associations.25 Previous clinical studies11–15
informed our present analysis. In 2001, we noticed in un-
treated hypertensive patients that the ACE D allele and
mutated ADD1 synergistically enhanced the pressor effect of
sodium loading.12 In a subsequent article,13 we reported that
the incidence of new-onset hypertension more than doubled
in ACE DD homozygotes compared with I allele carriers but
only in the presence of the ADD1 Trp allele. In cross-
sectional analyses of the same population, carriers of the 2
risk-conferring alleles had a thickened intima–media of the
femoral artery,15 as well as a higher serum creatinine concen-
tration and an increased 24-hour proteinuria.14 In never-
treated hypertensive patients, ACE DD homozygosity was
associated with microalbuminuria, but only in carriers of the
ADD1 Trp allele.11 Our current prospective findings with
hard events as the outcome of interest span a median
follow-up of 9 years and consolidate the concept that the
combination of ACE DD homozygosity and the ADD1 Trp
allele define a genetic constellation associated with a substan-
tially increased cardiovascular risk.
Our current findings not only clarified the combined
effects of the ACE I/D and ADD1 Gly460Trp polymorphisms
from a prognostic point of view but also provided the first
experimental evidence linking the known functionality of
these 2 polymorphisms.3,8–10,20,26,27 In line with clinical data3
and other studies of human tissues,8,20 we found a slightly
increased ACE activity in homogenates of human fibroblasts
carrying the ACE D allele. Rat experiments,26 in vitro
transfection studies,27 and studies of never-treated hyperten-
sive patients12 revealed that mutation of ADD1 leads to a
cellular dysfunction characterized by higher Na,K-ATPase
activity, hence, increased tubular sodium reabsorption in the
kidney.9,10 Expression of the hypertensive rat or human
variant of ADD1 into normal renal epithelial cells impaired
Na,K-ATPase endocytosis, which explains the higher so-
dium pump activity at the basolateral membrane10 and so-
dium retention and hypertension in the intact organism.
Cell transfection and molecular experiments in cell-free
conditions demonstrated that the ADD1 Trp allele compared
with the Gly allele modulates actin polymerization and
thereby leads to stiffening of the cytoskeleton supporting the
cell membrane.9 This effect, along with other molecular
mechanisms discussed in detail elsewhere,9,10 slows the rate
of endocytosis of membrane-bound proteins and lengthens
their residential time at the cell surface. Our current finding
that the membrane-bound ACE activity increased in the
presence of the ADD1 Trp allele in human fibroblasts, as well
as in transfected HEK cells, is therefore consistent with the
already available experimental evidence on the sodium
pump.9,10
In the circulating blood, renin is the rate-limiting enzyme
controlling the generation of angiotensin II.28 However, the
production of angiotensin II within tissues is regulated in a
different way. ACE at the cell surface locally generates
angiotensin II in the kidney,4–6 the arterial wall,7 and the
heart.8 The concentration of angiotensin II is much higher in
the renal interstitium and in the proximal tubular fluid than in
the circulating blood.4 Renal tubular cells express the bio-
chemical machinery, including ACE, which is necessary to
synthesize angiotensin II.4–6 Locally generated angiotensin II
probably plays a role in the tubuloglomerular feedback
mechanism.6 Expression of ACE in the arterial wall also
increases the local generation of angiotensin II.7 As suggested
by others,29–31 increased target organ damage in carriers of
the ACE DD genotype might be attributable to the exagger-
ated generation of angiotensin II within tissues. We suggest
that the ADD1 Trp allele probably facilitates this pathoge-
netic pathway.
The present study must be interpreted within the context of
its possible limitations. First, in comparison with other
prospective studies, our sample size and the number of events
was relatively small. As exemplified by the wide CIs (Table
3), the number of some end points might have been too small
to pick up a synergistic effect of ACE DD homozygosity and
mutated ADD1. Second, we could not study the effects of
ADD1 Trp homozygosity, because our population study
included only 68 homozygotes and because none of the
donors of fibroblasts was homozygous. Third we did not
prove causality and cannot exclude that genetic polymor-
phisms in linkage disequilibrium with the ACE or ADD1
genes contributed to our findings. Fourth, in long-term
surveys, the definition of events is likely to be less precise
than in short-term studies or clinical trials, in which end
points are collected via a single channel of information. On
the other hand, our outcome results showed internal consis-
tence, including those for total mortality, which is a binary
outcome not requiring any medical diagnosis. Use of a
prospective design in a cohort protects against confounding
by population stratification. Furthermore, our prospective
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epidemiological results corroborate a hypothesis indepen-
dently raised by studies in never-treated hypertensive pa-
tients,11,12 previous population surveys,13–16 and pharmacog-
enomic studies,32,33 and they are supported by animal
experiments26 and an established pathogenetic mechanism.9,10
Moreover, we replicated our initial findings in human fibro-
blasts in kidney cells of human origin transfected by the
wild-type and mutated human ADD1.
Perspectives
Our present findings might have repercussions for clinical
practice. The positive predictive value and attributable risk
associated with the combination of ACE DD homozygosity
and mutated ADD1 were 36.2% and 10.3%, respectively.
These estimates suggest that this particular genetic constel-
lation carries a risk comparable to that of established cardio-
vascular risk factors, such as smoking, hypercholesterolemia,
and hypertension. The factors explaining the high positive
predictive value associated with the combination of ACE DD
homozygosity and mutated adducin were the relative risk of
2.05 and the prevalence of 10.9%, which were substantially
higher and lower, respectively, than the corresponding values
for the classic risk factors. In a single-center study, we
observed that never-treated hypertensive patients investigated
under highly standardized conditions showed the largest
decrease in blood pressure in response to diuretic therapy if
they carried both the ACE I and ADD1 Trp alleles.32 Hyper-
tensive carriers of mutated ADD1 experience more cardio-
vascular complications than noncarriers,17,34 and they are
better protected if they are treated with diuretics instead of
drugs that do not antagonize the enhanced tubular sodium
reabsorption.33 We believe that our current findings might
help to pave the way to a pharmacogenomic and cost-saving
approach for the management of hypertension.
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